Skip to Main content Skip to Navigation
Journal articles

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

Abstract : Background. Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union. Methods. This 3-year follow-up study assessed the durability of sustained virologic response (SVR) (undetectable HCV RNA 12 or 24 weeks after treatment end), and evaluated the persistence of treatment-emergent NS3/4A protease inhibitor resistance in patients not achieving SVR following treatment with simeprevir plus PR in the parent study. The maintenance of SVR after the last post-therapy follow-up visit of the parent study (LPVPS) was assessed using HCV RNA measurements. The persistence of treatment-emergent NS3 amino acid substitutions in patients with no SVR at LPVPS was assessed using population sequencing. No study medications were administered. Results. Overall, 249 patients were enrolled (200 with SVR at LPVPS; 49 with no SVR at LPVPS); 40 patients discontinued prematurely (18 with SVR; 22 with no SVR). All 200 enrolled patients who achieved SVR in the parent study maintained SVR until the last available visit in this study (median follow-up time: 35.8 months). The treatment-emergent NS3 amino acid substitutions detected at time of failure in the parent study in 43/49 enrolled patients were no longer detected in 37/43 (86.0%) at the end of this study (median follow-up time: 179.9 weeks [41.3 months]). Conclusion. This 3-year follow-up study provides evidence for the long-term durability of SVR (100%) after successful treatment with simeprevir plus PR. Treatment-emergent NS3 amino acid substitutions became undetectable in the majority of patients. Trial registration:NCT01349465; ClinicalTrials.gov.
Document type :
Journal articles
Complete list of metadatas

Cited literature [27 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01700361
Contributor : Bmc Bmc <>
Submitted on : Sunday, February 4, 2018 - 5:21:08 AM
Last modification on : Wednesday, June 10, 2020 - 6:42:06 PM
Long-term archiving on: : Wednesday, May 2, 2018 - 8:47:35 PM

Files

12985_2018_Article_936.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Fabien Zoulim, Christophe Moreno, Samuel Lee, Peter Buggisch, Andrzej Horban, et al.. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection. Virology Journal, BioMed Central, 2018, 15 (1), pp.26. ⟨10.1186/s12985-018-0936-4⟩. ⟨inserm-01700361⟩

Share

Metrics

Record views

129

Files downloads

247